Diagens Biotechnology Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
174
- Stock Symbol
-
02526
- Share Price
-
$11.85
- (As of Thursday Closing)
Diagens Biotechnology General Information
Description
Hangzhou Diagens Biotechnology Co Ltd and its subsidiaries are involved in the development and commercialisation of medical imaging artificial intelligence technologies and medical imaging equipment. It has self-developed a diversified portfolio, including six medical imaging software products, three commercialized medical devices, four key reagents and consumables and two technology licensing offerings. Its Core Product, AI AutoVision, is an auxiliary diagnostic software designed to undertake intelligent analysis on chromosome karyotyping. The majority of the company's revenue is derived from Technology Licensing, mainly in the Chinese mainland.
Contact Information
Website
www.diagens.comCorporate Office
- Building A, Hangzhou Intelligent Health Valley, No. 609 Hongfeng Road, Donghu Street
- Linping District
- Hangzhou, Zhejiang 311100
- China
Corporate Office
- Building A, Hangzhou Intelligent Health Valley, No. 609 Hongfeng Road, Donghu Street
- Linping District
- Hangzhou, Zhejiang 311100
- China
Diagens Biotechnology Timeline
Diagens Biotechnology Stock Performance
As of 12-Nov-2026, Diagens Biotechnology’s stock price is $11.85. Its current market cap is $1.05B with 88.9M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $11.85 | $11.68 | $10.96 - $97.68 | $1.05B | 88.9M | 127K | -$0.20 |
Diagens Biotechnology Financials Summary
As of 30-Jun-2026, Diagens Biotechnology has a trailing 12-month revenue of $26.2M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,506,077 | |||
| Revenue | 26,197 | 22,864 | 9,805 | 7,469 |
| EBITDA | (1,301) | (4,644) | ||
| Net Income | (17,389) | (9,336) | (6,045) | (7,932) |
| Total Assets | 131,046 | 30,811 | 29,106 | 31,190 |
| Total Debt | 8,196 | 846 | 2,620 | 635 |
Diagens Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Diagens Biotechnology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Diagens Biotechnology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Diagens Biotechnology ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Software & Services
Industry
Rank
Percentile
Enterprise and Infrastructure Software
Subindustry
Rank
Percentile
Diagens Biotechnology FAQs
-
When was Diagens Biotechnology founded?
Diagens Biotechnology was founded in 2016.
-
Where is Diagens Biotechnology headquartered?
Diagens Biotechnology is headquartered in Hangzhou, China.
-
What is the size of Diagens Biotechnology?
Diagens Biotechnology has 174 total employees.
-
What industry is Diagens Biotechnology in?
Diagens Biotechnology’s primary industry is Medical Supplies.
-
Is Diagens Biotechnology a private or public company?
Diagens Biotechnology is a Public company.
-
What is Diagens Biotechnology’s stock symbol?
The ticker symbol for Diagens Biotechnology is 02526.
-
What is the current stock price of Diagens Biotechnology?
As of 12-Nov-2026 the stock price of Diagens Biotechnology is $11.85.
-
What is the current market cap of Diagens Biotechnology?
The current market capitalization of Diagens Biotechnology is $1.05B.
-
What is Diagens Biotechnology’s current revenue?
The trailing twelve month revenue for Diagens Biotechnology is $26.2M.
-
What is Diagens Biotechnology’s annual earnings per share (EPS)?
Diagens Biotechnology’s EPS for 12 months was -$0.20.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
